ArticleCancer medicine2025
Plexin Domain Containing 2, a Protein Specifically Expressed and Elevated in Human Pancreatic Cancer Tissue and Serum, Influences Cell Proliferation by Correlating With Cortactin.
Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Neural-immune-cancer crosstalk in pancreatic cancer: mechanisms and clinical translation.Frontiers in cell and developmental biology · 2026Review
- Plexin Domain Containing 2, a Protein Specifically Expressed and Elevated in Human Pancreatic Cancer Tissue and Serum, Influences Cell Proliferation by Correlating With Cortactin.Cancer medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
Abstract
backgroundPancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer with limited treatment options. Plexin domain containing 2 (PLXDC2), a tumor endothelial marker, has been implicated in several cancers, but its role in PDAC remains unclear. This study aimed to investigate the role of PLXDC2 and its interaction with cortactin in PDAC.
methodPLXDC2 and cortactin expression levels were assessed by immunohistochemistry in human PDAC tissues. Serum PLXDC2 levels were measured using ELISA. PDAC cell lines were transfected with PLXDC2 siRNA. The effects of PLXDC2 knockdown on cortactin and oncogene expression, as well as cell proliferation, were evaluated using quantitative PCR, Western blotting, immunofluorescence, and proliferation assays. Computational modeling with AlphaFold3 predicted the 3D structure of the PLXDC2-cortactin complex and designed inhibitory peptide.
resultsPLXDC2 was overexpressed in PDAC tissues and serum, with an AUROC of 0.987 compared to healthy individuals. PLXDC2 co-expressed with cortactin in human PDAC tissues. In PDAC cells, PLXDC2 knockdown led to decreased cortactin expression, followed by a reduction of oncogene (c-myc and Oct4) expression and proliferation. Computational analysis predicted that the SH3 domain of cortactin binds to the PSI domain of PLXDC2. Peptide-mediated inhibition of the PLXDC2-cortactin binding, by targeting the SH3 domain of cortactin, led to a reduction of oncogenic and proliferative genes.
conclusionsPLXDC2 is a potential biomarker of PDAC diagnosis. Targeting the PLXDC2-cortactin interaction may offer a novel therapeutic strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.